Related Experiment Video
Updated: Sep 19, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
WRN as a Novel Target of Synthetic Lethality: Current Advances and Future Perspectives
Yinghao Zhang1, Jiamin Zhang1, Cheng Tang1
1Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Abstract:
Werner syndrome (WS) is an autosomal recessive disorder caused by mutations in the Werner syndrome protein (WRN, also known as RecQ3) gene. As a pivotal member of the RecQ DNA helicase family, WRN facilitates essential processes in DNA replication, recombination, and repair, thus safeguarding genomic stability. In this perspective, we provide a critical analysis of WRN's structural and biological features as well as its regulatory networks. Synthetic lethality strategies targeting WRN show promise for treating microsatellite instability-high (MSI-H) cancers. We further spotlight recent developments in the discovery and design of WRN inhibitors, underlining their potential therapeutic applications.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Experimental RNAi
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

